Visa Inc vs Zimmer Biomet Holdings Inc — how do they compare? Visa Inc trades at $356.21 (market cap $685.71B), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Visa Inc is far larger — about 39.5× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.07%). Which is the better fit depends on your goals.
| V | ZBH | |
|---|---|---|
Market Cap | $685.71B | $17.36B |
Volume | 10,431,336 | — |
Sector | Financials | Health |
52-Week High | $365.14 | $107.71 |
52-Week Low | $295.52 | $79.58 |
Enterprise Value | $696.30B | $24.40B |
Dividend Yield | 0.74% | 1.07% |
Signals from Pluang's Aura AI — not financial advice
Visa (V) trades at $355.82, down 0.76% on the day, with a bullish technical outlook supported by moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $3.31 exceeding the $3.10 estimate. Revenue growth remains robust, reaching $40B in 2025, and profitability is high with a net income margin of 51.68%. Recent news highlights Visa's focus on AI-driven commerce and stablecoin partnerships, positioning it for future payment innovations.
The stock offers a compelling long-term investment case with 85% analyst buy ratings and a $396.70 consensus price target, implying 11% upside. Key risks include competitive threats from fintech and regulatory pressures. Visa's strong cash flow and dividend payments provide shareholder value, but investors should monitor execution on AI initiatives and macroeconomic impacts on consumer spending.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →